Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (NASDAQ: ILMN) is described by the company as a global leader in DNA sequencing and array-based technologies, serving research, clinical, and applied markets across genomics, multiomics, and proteomics. This news page aggregates recent press releases and announcements so readers can follow how Illumina’s technologies, collaborations, and financial disclosures evolve over time.
Company news highlights include product and platform launches, such as Illumina Connected Multiomics, a cloud-based software platform for analyzing and visualizing multiomic data, and Illumina Protein Prep, which the company states delivers broad coverage of the blood proteome and supports large-scale genomics studies. Illumina has also announced the Illumina Billion Cell Atlas, a large genome-wide genetic perturbation dataset developed through its BioInsight business to support AI-driven drug discovery in collaboration with pharmaceutical partners.
Investors can use this news feed to track Illumina’s preliminary financial results, earnings announcements, and capital markets activities, as reflected in press releases tied to quarterly and annual results and conference presentations. The page also captures updates on strategic agreements and acquisitions, including Illumina’s planned acquisition of Standard BioTools’ aptamer-based and functional proteomics business, as described in SEC filings and related communications.
In addition, Illumina’s news often covers leadership appointments, regulatory and market developments, and collaborations with genomics and population health partners such as MyOme. By reviewing these updates in one place, readers can better understand how Illumina positions its sequencing, multiomic, and proteomic offerings and how its corporate strategy and partnerships may influence its role in genomics and precision medicine. Bookmark this page to review new company-issued information as it becomes available.
Illumina (NASDAQ: ILMN) introduced the Illumina Billion Cell Atlas on January 13, 2026, a genome‑wide genetic perturbation dataset built to accelerate AI‑driven drug discovery.
The first tranche targets 1 billion individual cells across 200+ disease‑relevant cell lines, using CRISPR to perturb ~20,000 genes. Illumina plans a 5 billion cell resource over three years and expects to generate ~20 petabytes of single‑cell transcriptomic data within a year, processed via DRAGEN and hosted on Illumina Connected Analytics. AstraZeneca, Merck, and Eli Lilly are founding participants under an alliance framework.
Illumina (Nasdaq: ILMN) reported preliminary unaudited results for Q4 and fiscal 2025 ahead of its Jan 13, 2026 J.P. Morgan presentation. Q4 revenue ~$1.155B (up 5% vs Q4 2024; 4% constant currency) and ex-China Q4 ~$1.100B (up 7%). Fiscal 2025 revenue was approximately $4.34B (flat year-over-year) with ex-China $4.10B (up 2%). Preliminary GAAP diluted EPS: $2.14–$2.17 (Q4) and $5.42–$5.45 (FY); preliminary non-GAAP diluted EPS: $1.27–$1.30 (Q4) and $4.76–$4.79 (FY). Results are unaudited and subject to final audit; full results due Feb 5, 2026.
Illumina (NASDAQ:ILMN) will release fourth quarter and full year 2025 financial results after market close on Thursday, February 5, 2026.
Management will host a conference call at 1:30 PM PT / 4:30 PM ET on the same day. Investors can access a live webcast via the company's Investor Info website or the provided link. A replay will be posted on the website and remain available for at least 30 days.
Illumina (NASDAQ: ILMN) appointed Eric D. Green, M.D., Ph.D. as Chief Medical Officer, effective February 2, 2026. Dr. Green will report to the CEO, join the Executive Leadership Team, and lead efforts to expand clinical genomics, increase diversity of genomics data, and advance the company's medical strategy globally. The company also announced the departure of chief commercial officer Everett Cunningham, with CEO Jacob Thaysen acting as interim chief commercial officer.
Illumina (NASDAQ: ILMN) on January 6, 2026 announced Illumina Connected Multiomics, a cloud-based research software platform for integrated multiomic and multimodal analysis.
The platform, officially launched last month after input from 40 early access users, can aggregate thousands of multiomic samples, supports single-cell and spatial analyses, includes DRAGEN secondary analysis, and adds AI-enabled variant interpretation via PrimateAI and PromoterAI.
Illumina says the software aims to reduce time, cost, and complexity for researchers and enable reproducible interactive visualizations and scalable workflows for discovery and precision medicine.
Illumina (NASDAQ: ILMN) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The management presentation is scheduled for 7:30 a.m. PT (10:30 a.m. ET) with a Q&A at approximately 7:50 a.m. PT (10:50 a.m. ET). The live webcast will be available via the Events & Presentations section of Illumina's investor website, and a replay will be archived on the site for at least 30 days following the event.
Illumina (NASDAQ: ILMN) announced a collaboration and strategic investment in MyOme to support MyOme's Proactive Health (MPH) Trial and expand clinical genomics products. The MPH Trial aims to enroll beginning in 2026 and will test whole‑genome sequencing (WGS) plus MyOme's AI‑integrated risk models (IRMs) for earlier detection and prevention across cancers, cardiometabolic and rare diseases. Health economic modeling cited in the announcement estimates potential U.S. cost savings of more than $200 billion annually if WGS+IRM adoption is broad. The deal also notes continued financing support from partners including Natera, Sequoia Capital and The Duquesne Family Office.
Illumina (NASDAQ: ILMN) announced a collaboration and strategic investment in MyOme, announced Dec. 11, 2025, to support MyOme's Proactive Health (MPH) Trial and commercial product expansion.
The MPH trial aims to begin enrollment in 2026 and will evaluate whole‑genome sequencing (WGS) plus MyOme's AI‑integrated risk models (IRMs) for common chronic disease, cancer and rare disease. Health economic modeling cited in the announcement suggests potential U.S. savings of more than $200 billion per year from broad WGS+IRM adoption; the release notes U.S. annual healthcare spend of about $5 trillion. The financing also lists continued support from Natera, Sequoia Capital and The Duquesne Family Office.
Illumina (NASDAQ: ILMN) and collaborators published a Nature study on Nov 12, 2025 showing whole-genome sequencing (WGS) with DRAGEN capture nearly 90% of genetic signal across 34 common diseases and traits, addressing the "missing heritability" gap. The analysis used 347,630 WGS samples from UK Biobank and replication in the Alliance for Genomic Discovery.
Key findings: WGS outperformed whole-exome sequencing and arrays, with WES explaining 17.5% of genetic variance, arrays missing 20–40% of some rare alleles, and WGS recovering >30% of rare-variant heritability for HDL and LDL. Advanced AI tools (PrimateAI-3D, DRAGEN) improved rare-variant interpretation and drug-target discovery.
Illumina (NASDAQ: ILMN) will present at the Wolfe Research Healthcare Conference 2025 on November 19, 2025. Executives will take part in a fireside chat at 6:20 AM PT (9:20 AM ET).
The event will be webcast via the Investor Info section of Illumina's website at investor.illumina.com. A replay will be posted after the event and remain available for at least 30 days.
FAQ
What is the current stock price of Illumina (ILMN)?
What is the market cap of Illumina (ILMN)?
